Emily Estrada

Results from the phase 1/2 ASCERTAIN-V trial demonstrated that an all-oral regimen of decitabine and cedazuridine plus venetoclax produced meaningful

Results from a phase 3 trial demonstrated that fovinaciclib plus letrozole or anastrozole significantly improved progression-free survival (PFS) compared

Design/Population: The phase 2 J201 trial evaluated safusidenib, a selective mutant IDH1 inhibitor, in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant glioma.

Results from cohort 3 of the phase 1/2 ITCC-059 trial demonstrated that inotuzumab ozogamicin produced high response rates with a manageable safety

Results from a retrospective, real-world study demonstrated that azacitidine produced comparable efficacy and tolerability in elderly and younger

A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...

Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...

The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.

Based on results from the phase 3 PSMAddition trial, the US Food and Drug Administration (FDA) approved lutetium Lu 177 vipivotide

On August 6, 2026, the US Food and Drug Administration (FDA) granted accelerated approval to vusolimogene oderparepvec (Tudriqev; Replimune) plus